1. Home
  2. RKLB vs ONC Comparison

RKLB vs ONC Comparison

Compare RKLB & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocket Lab USA Inc.

RKLB

Rocket Lab USA Inc.

N/A

Current Price

$70.53

Market Cap

41.3B

Sector

Industrials

ML Signal

N/A

Logo BeiGene Ltd. American Depositary Shares

ONC

BeiGene Ltd. American Depositary Shares

N/A

Current Price

$358.81

Market Cap

40.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RKLB
ONC
Founded
2006
2010
Country
United States
Switzerland
Employees
N/A
12000
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.3B
40.6B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
RKLB
ONC
Price
$70.53
$358.81
Analyst Decision
Buy
Strong Buy
Analyst Count
20
28
Target Price
$109.37
★ $432.80
AVG Volume (30 Days)
★ 16.1M
320.8K
Earning Date
11-09-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
2.63
★ 140.43
EPS
N/A
★ 0.31
Revenue
★ $601,799,000.00
$238,387,000.00
Revenue This Year
$59.24
$26.33
Revenue Next Year
$42.18
$14.36
P/E Ratio
★ N/A
$1,196.77
Revenue Growth
37.96
★ 22179.16
52 Week Low
$37.57
$253.95
52 Week High
$150.85
$385.22

Technical Indicators

Market Signals
Indicator
RKLB
ONC
Relative Strength Index (RSI) 51.50 60.26
Support Level $64.94 $327.01
Resistance Level $77.33 $380.00
Average True Range (ATR) 3.29 6.86
MACD 0.80 0.75
Stochastic Oscillator 64.00 87.88

Price Performance

Historical Comparison
RKLB
ONC

About RKLB Rocket Lab USA Inc.

Rocket Lab Corp is engaged in space, building rockets, and spacecraft. It provides end-to-end mission services that provide frequent and reliable access to space for civil, defense, and commercial markets. It designs and manufactures the Electron and Neutron launch vehicles and Photon satellite platform. Rocket Lab's Electron launch vehicle has delivered multiple satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. The business operates in two segments Launch Services and Space Systems. Geographically it serves Japan, and rest of the world and earns key revenue from the United States.

About ONC BeiGene Ltd. American Depositary Shares

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.

Share on Social Networks: